An interventional study of Percutaneous Coronary Intervention and Percutaneous Coronary Intervention using R-One assistance in Coronary Artery Disease and Percutaneous Coronary Intervention, sponsored by Robocath. Completed at 6 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-08.
Sponsored by Robocath · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 218 studies in Coronary Artery Disease with a site in France — 28 open to participants now, 44 under way, 6 of them phase 3. Coronary Artery Disease · France.
Among the 218 studies in Coronary Artery Disease with a site in France, this one is the 125th largest by enrollment of the 158 interventional ones that give a count, is one of 8 that started in 2019, is one of 89 with no phase, and was the 159th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →28 of the 218 studies in Coronary Artery Disease with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 30–60
Teleflex · Sites in France, United States, Latvia and 1 more country
Ages 18–80
Vincent ROULE · Sites in France
Ages 65+
Shunmei Medical · Sites in France, Germany, Poland and 1 more country
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
218 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 38 · Phase 4 23
First in 2000; this study’s year is marked. 8 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 300 across the 158 interventional studies, 400 across the 59 observational. Of the 152 that completed or were terminated, 40 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
123 of 218 have an industry lead sponsor. The 10 most frequent:
Robocath is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Robocath has 2 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
11 of the studies in Coronary Artery Disease with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05952206Phase 3iVascular S.L.U.Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy | 2027-01-13 |
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT04604782GE HealthcareA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients | 2026-12 |
| NCT03820492Insel Gruppe AG, University Hospital BernComparison of Optical Coherence Tomography-derived Minimal Lumen Area, Invasive Fractional Flow Reserve and FFRCT | 2026-12-31 |
| NCT05698732Fundación EPICCoroflex® ISAR NEO PMCF Study | 2027-02-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 218 studies in Coronary Artery Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a Prospective, Multi-center, Single-arm clinical study, in patients with Coronary Artery Disease, including patients with silent ischemia (excluding STEMI), who qualify for elective Percutaneous Coronary Intervention (PCI), aimed to assess the Safety and Efficacy of the R-One device in elective PCI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients treated with robotic assistance
Procedure: Percutaneous Coronary Intervention · Device: Percutaneous Coronary Intervention using R-One assistance
PCI with robotic assistance
PCI with robotic assistance
Safety Endpoint: Number of patients with absence of Intra-procedural complications (Dissection, Thrombus, Air embolus, traumatic aorta)
Absence of Intra-procedural complications (Dissection \>/= NHLBI type D, perforation, decrease of TIMI flow (\</= 2), acute occlusion, visible thrombus formation, significant air embolus, traumatic aortic or Left Main dissection by guiding catheter
Time frame: Peri-procedure
Efficacy Endpoint: Number of Patients with Procedure technical success
Procedure technical success defined as the successful advancement and retraction of all PCI devices (guidewires, balloon catheters and stents) and the successful treatment of all the target lesions using the R-One system and without conversion to manual operation
Time frame: During Procedure
Number of patients with Absence of each type of Intra-procedural complication (Dissection, Thrombus, Air embolus, traumatic aorta)
Component of the Primary Safety Endpoint: Absence of Intra-procedural complications (Dissection \>/= NHLBI type D, perforation, decrease of TIMI flow (\</= 2), acute occlusion, visible thrombus formation, significant air embolus, traumatic aortic or Left Main dissection by guiding catheter
Time frame: During Procedure
Procedure duration
Time between arterial sheath introduction and sheath removal
Time frame: During Procedure
Robot duration
From the time when the robot begins to manipulate the guidewire to the time when the last guidewire is removed
Time frame: During Procedure
Radiation exposure using dosimeters (Patient Radiation, Robot Dose, Procedure Dose)
Patient and Operator
Time frame: During Procedure
Contrast Volume in mL
Measure of the volume of injected contrast media
Time frame: During Procedure
Rate of Bleeding or Vascular Complications
BARC definition
Time frame: Up to 1 month
Rate of Device Oriented Composite Criteria (Cardiovascular Death, Myocardial Infarction (peri-procedural and spontaneous), non clearly attributed to a non target or clinically driven target lesion revascularization)
ARC 2 definition: Cardiovascular Death, Myocardial Infarction (peri-procedural and spontaneous), non clearly attributed to a non target or clinically driven target lesion revascularization
Time frame: Post-Procedure, 1 month
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2019 to primary completion in Nov 2021, 25 months.
Of 177 industry-sponsored interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 40. This study's 25 months is close to that.
Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Robocath